Good morning, everyone, and thank you for joining us to discuss Tilray Brands, Inc Financial Results for the 2022 Fiscal Fourth Quarter ended May 31st, 2022. All lines have been placed on mute to prevent any background noise. After the speaker's remarks, there will be a question-and-answer session for analysts and investment firms conducted via audio, and participating retail shareholders conducted through the Say Technologies platform. Question submission and uploading through the Say Technologies platform has already been concluded, and the company will read aloud and answer the top questions. Ms. Noorata, you may begin the conference.
Thank you and good morning. By now, everyone should have access to the earnings release, which is available on the I nvestors section of Tilray's website at tilray.com and has been filed with the SEC and SEDAR. On today's call, please note that we will be referring to various non-GAAP financial measures which can provide useful information for investors. However, the presentation of this information is not intended to be considered in isolation or as a substitute for the financial information presented in accordance with GAAP. Today's earnings press release contains a reconciliation of each non-GAAP financial measure to the most comparable measure prepared in accordance with GAAP. In addition, we will be making numerous forward-looking statements during our remarks and in response to your questions. These statements are based on our current expectations and beliefs and involve known and unknown risks and uncertainties, which may prove to be incorrect.
Actual results could differ materially from those described in these forward-looking statements. The text in our earnings press release issued today includes many of the risks and uncertainties associated with such forward-looking statements. Now, I'd like to turn the call over to Tilray Brands' Chairman and CEO, Irwin Simon.
Thank you, Berrin, and good morning, everyone. Thank you all for being with us this morning. I'm joined on this call by several key members of our senior leadership team, who you'll be hearing from shortly, including Denise Faltischek, Chief Strategy Officer and Head of our International Business, who will discuss our operational strengths across key global markets and the outlook for legalization across Europe. Blair MacNeil, President of our Canadian Business, who will update you on the Canadian cannabis market. And finally, Carl Merton, Chief Financial Officer, who will provide a financial update, including our progress in realizing cost synergies. Before I turn the call over to Denise, I'd like to discuss three items.
First, the work we have done over the course of this fiscal year to optimize our global business and significantly improve our operational performance and lay the groundwork for sustainable, profitable growth in 2023 and beyond. Second, I will discuss our strategic alliance with HEXO and the important role it plays in our future growth plans. Third, our plan to generate up to $4 billion in revenue, depending upon federal legalization in the U.S. and Germany at the end of fiscal year 2024. With that, let me start off by saying that fiscal 2022 was a period of great execution and accomplishments in building Tilray Brands, world-leading cannabis CPG platform. Over the past year, we've been laser-focused on optimizing our global operations and pursuing our most profitable core businesses across Canada, Europe, and the U.S.
This work has included both deprioritizing and divesting lower growth legacy assets, including duplicate production facilities, while renewing investments across our four pillars, including medical, adult use, wellness, and beverage alcohol. Not only are we world-class brands and businesses in these areas driving recent market share gains and growth, but we have also entered into key strategic transactions that are bolstering revenue through improved cultivation, brand building, and distribution, while also driving productive efficiencies. The outcome of this work, as you'll hear about from the team on today's call, is evident on our performance. To give you some highlights, we had a record year with net revenue growing 22% to reach $628 million. This reflects our market-leading position in Canada, our market-leading position in Germany, and the growth of our international cannabis sales overall by 200% compared to Q4 in fiscal 2021.
Our growth in our Tilray wellness segment with our Manitoba Harvest business, as well as the contribution from our award-winning beverage alcohol we acquired over the past two years. Adjusted EBITDA increased 18% to $48 million in fiscal 2022. Of note, the fourth quarter of this year marked our 13th consecutive quarter of positive adjusted EBITDA. We ended the year with a strong balance sheet with more than $400 million in cash. Very important, we delivered $85 million in cost savings, which exceeded our original target of 80 and were substantially accelerated timeline compared to earlier plans.
We now expect to deliver $100 million in cost savings by the end of fiscal 2023, and we believe we'll be operating free cash flow positive at that point as well. As Carl will walk you through in a few moments, we're taking a non-cash impairment charge of $395 million in fiscal 2022 related to both market conditions and the work that we have done to optimize our operations in order to ensure that Tilray Brands is best positioned to continue to lead the global cannabis industry and as legalization continues to accelerate. Moving along to HEXO. Our acquisition of HEXO senior secured convertible notes closed on July 12th of this year.
In short, this transaction provides us with broad commercial and financial benefits, including strengthening product innovation, brand building, and distribution in Canada and international markets, and eventually in the U.S. markets upon legalization through leveraging our collective expertise and know-how, and capitalizing on growth opportunities that stem from having expanded world-class CPG offerings. In addition to being immediately accretive to our earnings, financial benefits of HEXO transaction, including up to $80 million in shared cost savings synergies within the next two years, as Tilray will now complete production and processing products for HEXO, and HEXO will source all of its non-Canadian and non-U.S. cannabis products exclusively from Tilray. HEXO will pay Tilray Brands an annual fee of $80 million for advisory services in each of the next four years with respect to cultivation, operation, and production matters. Carl will discuss this in more detail.
Also, I want to share that as a result of our foresight and the work we've done to optimize our business over the course of 2022, we believe we have a strong foundation upon which to achieve our strategic plan to reach $4 billion in revenue by the end of fiscal 2024, depending, of course, upon federal legalization of adult-use in the U.S. and Germany. As we've discussed previously, this will be accomplished by building a truly global CPG and cannabis company with a portfolio of best-in-class medical, adult-use, wellness, and craft beverage alcohol brands that address the needs of patients and consumers.
In achieving this objective, we are fortunate to already have many enviable attributes, each of which we sharpened over the course of fiscal 2022, that demonstrates the power of Tilray Brands, including our proven brands and complete product offerings, our status as a leading low-cost cannabis producer, our strategic footprint and operational scale, our ability to accelerate international growth opportunities, our growing presence and infrastructure within the U.S. CPG market, and our proficiency in generating substantial cost savings synergies in pursuit of long-term profitability. Of course, none of this would be possible if I was not surrounded by an experienced management team who can build upon the lessons of better for you, CPG, and beverage alcohol to execute against repeatable growth formulas within medical cannabis, adult-use cannabis, adult-use adjacencies, and wellness.
To provide an overview of our strategic initiatives by region, in Europe, we have a $1 billion opportunity based upon momentum growth, strategic initiatives, and adult use legalization. In Canada, we have a clear path to achieve our goal of delivering $1 billion in revenue. It includes working aggressively to further solidify market-leading positions in adult use, gain back market share through converting illicit consumers to the legal market, and growing our business among current and potential customers, while also continuing to bolster our medical business. Its four pillars include delivering continued product innovation and category leadership, investing in retail partnerships by educating budtenders through an enhanced outreach and curating offerings to provide retailers with the highest velocity products. Producing best-in-class quality products in scaled, low-cost production facilities in which we can implement synergies.
Finally, as it relates to medical, expanding our relationship with patients and physicians to bolster our market position while keeping our product assortment fresh and innovative as we work to advance education responsibility that impact regulation. Blair will discuss the Canadian cannabis market in further detail. In the U.S., where 91% of adults say cannabis should be legalized for medical or adult use, and 60% of adults across a variety of demographic groups believe cannabis should be fully legalized, we see a market poised for growth, supported by a state-by-state trend towards legalization. We believe that we can reach our target revenues by the end of fiscal year 2024 through a broad set of cannabis-focused CPG and craft beverage brands, and additional revenue in adult-use cannabis, pending federal legalization. Federal legalization would certainly be a watershed event for Tilray Brands and the industry.
Given the near-term uncertainty in seeing actual legalization reform, we're pursuing optionality, which we view as the next best thing. We have a considerable adult use adjacency through our craft beverage, alcohol and wellness business, which include key U.S. and global assets such as SweetWater, Breckenridge Distillery, Manitoba Harvest, which together are available in all 50 states and Washington, D.C. As we've discussed previously, our investment in MedMen during year 2022 exemplifies this approach, and we can build upon, given our strong balance sheet and leadership expertise in operations, profitable CPG businesses, and growing brands that consumers love to pursue additional acquisition opportunities across the U.S. Together, our growing U.S. CPG platform represents a portfolio of award-winning and highly sought-after consumer brands, a strong and robust infrastructure, a broad global distribution footprint, hands-on CPG expertise and operational excellence.
Today, our U.S. CPG businesses combined are high margin, EBITDA, and cash flow positive, as well as good adjacencies to the cannabis industry. Upon legalization and collectively, they have generated over $130 million in revenue during fiscal year 2022, and nearly $60 million in gross profit. Our beverage alcohol brands consist of SweetWater, the number one ranked brewery in the Southeast, and the nation's tenth-largest craft brewer. Breckenridge Distillery, which recently celebrated two double gold and one gold medal in the 2022 San Francisco World Spirits Competition, the largest spirits competition in the world. Alpine and Green Flash, which are two iconic West Coast craft brands. Our wellness business consists of Manitoba Harvest, which is a pioneer and leader in branded hemp-based foods.
Through recent expansions, SweetWater is now available in 42 states, including California, which is the number one beer market in the U.S. SweetWater also operates a new 32,000 sq ft production facility and taprooms in Fort Collins, Colorado, along with a new taproom at the Denver International Airport. The brand commands a loyal customer following and go-forward plans for SweetWater include continuing to launch innovative products, a new spirit-based ready-to-drink beverages, continued westward penetration in the U.S. while expanding our presence in Canada and other international markets, improving production utilization, and evaluating strategic acquisition. Breckenridge Distillery is widely known for its award-winning bourbon whiskey collection and innovative craft spirits portfolio, including bourbon whiskey, gin, and vodka. Distribution already reached across 50 states, and the brand is able to benefit from distribution synergies when paired with SweetWater.
We are confident that this will drive growth both now and in the future. Finally, Manitoba Harvest is the world's leading hemp brand with production distribution across 17,000 stores in North America and a 50% share in the hemp seed and 15 established markets. Since the business combination, Manitoba has not only been stabilized, but has experienced dramatic trajectory change in measured channel with further opportunities to extend into adjacencies. We have also managed costs, implemented pricing actions amidst a rising input cost environment, and decreasing our reliance on big box distribution points. We will leverage these strong brands and their distribution system to grow our U.S. Tilray wellness business that will parlay it into CBD beverages, CBD personal care products, and related adjacencies.
Upon federal legalization in the U.S., we'll have a clear advantage to lead in the U.S. market and strategic infrastructure operations in place to parlay into the THC-based products as well. Before I turn the call over to the team, I'd like to reiterate what we announced this morning. The company expects to generate $70-$80 million of adjusted EBITDA and will be free cash flow positive in our operating business units in fiscal year 2023. With that, let's hear from Denise Faltischek, our Chief Strategy Officer and Head of International Business. Denise.
Thank you, Irwin, and good morning, everyone. Internationally, our strategic presence and position continues to accelerate powerful growth, and the signs continue to point to a bright future as we expand our international footprint. The European cannabis industry is heading into a period marked by widespread legalization, innovation, and considerable economic growth. According to Prohibition Partners, sales of medical cannabis in Europe are expected to be approximately EUR 354 million this year, growing to EUR 2.3 billion by 2026. Sales of adult use cannabis in Europe are expected to reach EUR 1.5 billion by 2026, with more progressive cannabis legislation being introduced across the continent.
As an international market leader, we at Tilray see ourselves as a frontrunner in the further development of this profitable market, given our proven track record. We recognized the signs of the times early on and made several strategic investments that are now resulting in first-mover advantages. Our operational strength is reflected along the entire value chain. With our leading medical cannabis brands, strong distribution network in Germany with CC Pharma, an end-to-end EU GMP supply chain, which includes two state-of-the-art EU GMP production facilities in Portugal and Germany, with opportunities for expansion at each facility. We are well-positioned to continue to pursue international growth opportunities. In Europe today, we have one of the leading portfolios of medical cannabis whole flower and oil extract products to meet our patients' needs, and we plan to continue to build on this strong foundation and maintain our leadership position.
During Q4, this unique setup led to international medical revenue increasing 205% compared to last year's Q4. Down from Q3 due to shipments in Israel in the prior quarter, which we made the conscious decision not to repeat in Q4 due to the severe deterioration of market conditions within Israel, with medical cannabis sales and pricing declining. The outlook for other international markets is more promising. Now is the time to seize the opportunities and move the European cannabis industry forward. The potential is enormous, especially in Germany as a central market, which is expected to remain the largest medical cannabis market in Europe, and should also emerge as one of the largest adult use markets upon legalization. We are already the leader in medical cannabis and number one in revenues in both flower and oil categories.
Based on Insight Health sales data, Germany's leading provider of health industry, pharmacy, and medical cannabis sales data, Tilray has a market share of approximately 20% in Germany across our flower, extracts, and dronabinol products. We are ready to make our contribution to the recreational market, for which we have created the best conditions. On the one hand, the operational strength of our business model with two state-of-the-art EU GMP facilities allows us to exponentially ramp up our capacity to meet the demand for medical and adult use cannabis.
On the other hand, given our market leadership in the German market today, our well-established relationships with German regulators, where we have already proven ourselves to be the trusted partner, and our expertise in adult-use cannabis that we developed in Canada, we believe we are well-positioned to establish ourselves as a market leader in the broadly legalized adult-use cannabis market in Germany and seize a sizable portion of that market. This puts us in a unique position in Germany, which continues to state its intention to legalize adult-use cannabis. With Germany's Health Minister, Dr. Karl Lauterbach, announcing that a draft bill on adult-use cannabis could be published in late fall of 2022. However, we believe in that instance, the first commercial sale would not commence until the beginning of calendar year 2024.
Also, outside of Germany, we firmly believe that Europe is well-positioned to assert itself as a new hub for cannabis with regulatory reforms across the continent progressing. Many European countries have expressed a clear political ambition to broadly legalize adult use cannabis. This is likely to be the start of a wave of change in Europe. In fact, we think all of Europe could legalize medical use cannabis within the next two years or sooner, with certain countries legalizing adult use shortly thereafter. A few highlights in the quarter for our international business across various countries. In France, we estimate that the French market is roughly the size of Germany. We believe that today we are serving approximately 25% of the patients within the experiment based on information provided by the ANSM.
We also believe that France will legalize next spring when the experiment ends, and we are well-positioned to take a leadership role there. In the U.K., we have the most comprehensive mix of medical cannabis products. We also launched POLLEN, a CBD lifestyle brand on Amazon U.K. with a mix of CBD gummies and drink drops in three signature lines. In Poland, I am pleased to announce that we recently received approval for our regulatory submission in Poland, and will begin importing Tilray-branded and white label medical cannabis products into Poland commencing in Q2. In Israel, we continue to evaluate the market and are well-positioned to serve Israeli patients with the high-quality whole flower products from our Portugal facility, which is CUMCS certified compliant in addition to being EU GMP.
We have stayed abreast of the continuously changing regulatory requirements and have prepared our operations and are compliant with the regulation changes on testing that take effect in the fall. Finally, in Australia, we have expanded our medical cannabis product offerings to now include a complete range of medical cannabis whole flower to meet patient needs and are seeing great acceptance of our products. More importantly, we are one of the few providers of medical cannabis to Australia that are already compliant with the EU GMP regulations to take effect next June. With that, I'll now turn the call over to Blair MacNeil, President of our Canadian business. Blair?
Thank you, Denise, and hello, everyone. Over the last four years, a $5 billion legal market for cannabis in Canada has been created, which is an incredible achievement. However, this still represents a little more than half the total cannabis market in Canada, and the differential provides a significant revenue opportunity ahead. Not to mention the estimated 40% of consumers of legal age who have not yet entered the category. Still, this is a challenging operating environment characterized by an oversupply of cannabis, unreasonable regulatory barriers, and punitive excise taxation exacerbated by price compression. For the average licensed producer, excise is almost one-third of gross revenue. Despite this, we continue to see growth in the number of LPs and retail outlets in Q4. Additionally, Q4 had more new products launched in the marketplace in any period since legalization.
Despite an environment of rising costs in all aspects of their lives, cannabis consumers continue to benefit from higher quality cannabis at reduced prices, while governments continue to benefit from significant taxation revenue. This is not sustainable, and we see significant consolidation on the LP front over the next 12 months. In Q4, our retail market share declined to 8.3% from 10.2% in this sequential period because of these challenging industry conditions, SKU rationalization, and discontinuation of partner brands. Our number two market share in Canada and leading top five positions across numerous adult-use categories, including flower, pre-rolls, and vapes based on recent Hifyre sales data suggest to us that our strategies are beginning to deliver. In May, we saw the first of over 23 flower beta strains come to the market.
Monkey Butter and Sweet Berry Kush hit limited markets with great success. We experienced a 123% increase in forecasted sell-through and completely sold through in Q4 versus extending into Q1. We have an additional 46 strains in our alpha program, reinforcing our commitment to a flower innovation pipeline for years to come. You will recall the majority of our share loss in FY 2022 was due to gaps in flower innovation, and we are confident this will reverse the trend moving forward. We are encouraged that in June we experienced a reversal in trend and began regaining market share, a direct reflection of the flower investments we have been making. Additionally, we have been recently able to account for the gap in Hifyre data as it relates to Quebec.
When we adjust for the overstatement of competitive LP share in Quebec, Tilray regained its number one market share nationally for the month of June. Our plan to win in Canada is based upon an integrated consumer-first approach that leverages our scale and best-in-class manufacturing to drive profitability and share leadership over time. This begins with a deep understanding of the consumer need, occasion, and functional benefit to drive our portfolio strategy of brands. Our consumer insight research project is nearing completion, which will form our thinking for brand strategy. We utilize this strategy to develop our portfolio prioritization and innovation pipeline across all product categories and consumers. During Q4, we brought exciting innovation to the market across all categories, beginning with Solei Bites, the brand's first foray into edibles and the first ready-to-eat THC edible available at the SQDC, Quebec's sole legal retailer for cannabis products.
We expanded Good Supply's best-selling cannabis portfolio with the launch of new high-potency products, including liquid wax vapes and exclusive new flower strains available in select markets across Canada. Finally, last month, we launched CBN Night Oil under the Aphria Medical Cannabis brand. This is just a small sample of the innovation we will launch in the coming months ahead. In FY 2023, we expect to launch over 100 SKUs of innovation nationally, improving our innovation share of revenue to a market-leading 20% for licensed producers of our size. This consumer-first innovation pipeline will continue to identify white space opportunities for years to come. As we have consistently communicated, budtenders are a key part of our strategy.
We are making investments in driving awareness through social media and digital and educating budtenders through store visits and product knowledge sessions while developing a CRM budtender database for focused communications. Through our market-leading coverage with Great North, we conducted almost 3,000 product knowledge sessions with budtenders on our innovation and product portfolio in Q4. This resulted in over 6,200 new points of distribution. Finally, we have a relentless focus on end-to-end costs at Tilray. Early in Q4, we identified the opportunity to optimize our cost base even further. We have put in place an additional $30 million plan, which is over and above our Tilray-Aphria and our Tilray-HEXO synergies. This demonstrates our commitment to managing gross margin amid an evolving retail environment. These plans are already underway, realizing $5 million in savings in the first six weeks of Q1.
I will now turn the call back over to Carl Merton, Chief Financial Officer, to discuss financials in greater detail. Carl?
Thank you, Blair. Our results for both Q4 and fiscal year 2022 demonstrate our strength in having a diversified business across distinct operating segments, along with the traction we have made in implementing greater efficiencies into our organization despite ongoing market challenges. Before I review our financials, let me first remind everyone for one final time that because of the arrangement between Aphria and Tilray in fiscal year 2021, our results in both the prior fiscal quarter and prior fiscal year consist of three months and 12 months of Aphria's financial statements, but only 1 month in both reporting periods of Tilray's operating results. Our financial results follow U.S. GAAP and are presented in U.S. dollars. In addition, throughout our call today, we will reference both our financial results in accordance with GAAP as well as our non-GAAP adjusted financial results.
Our earnings press release contains a reconciliation of our reported financial results under GAAP to the non-GAAP financial measures identified during our remarks. Beginning with the top line, our Q4 net revenue grew 7.8% to $153.3 million compared to the prior year quarter. As I just said, the comparison itself is not fully apples to apples because Q4 of fiscal 2021 contains only one month of contributions from Legacy Tilray and does not include Breckenridge results. Our Q4 net revenue continued to be negatively impacted by the ongoing strength of the U.S. dollar, particularly given our biggest revenue sources' native currencies are the euro and the Canadian dollar.
For example, if the average foreign exchange rate this year was equal to the rate in the prior year for the same period, we would have reported an additional $9.5 million in net revenue and reported an additional $0.7 million in adjusted EBITDA for Q4. Adjusted gross profit increased 16.7% to $50.5 million in Q4 from $43.3 million in the prior year quarter, while adjusted gross margin increased 250 basis points to 32.9% from 30.4%. We believe both of these profitability metrics should continue demonstrating improvement as more of our cost-saving programs are completed. Net loss was $457 million in Q4 compared to net income of $33.6 million in the prior year quarter.
The variance is due largely to impairment, amortization, and other non-cash changes in fair values, offset partially by lower transaction costs in the quarter. Q4 adjusted EBITDA was $11.5 million, down 12.8% from the prior year quarter, extending our track record of positive adjusted EBITDA to 13 quarters. Our positive adjusted EBITDA is a function of higher contributions to adjusted gross profit from our operating business segments, coupled with our strong focus on realizing operational and other efficiencies through integrations as we have discussed over the past few quarters. Contributing to our ability to report positive adjusted EBITDA this year was the work we did achieving our synergy targets as part of the Aphria-Tilray arrangement.
We finished fiscal 2022 realizing $85 million of synergies towards our revised target of $100 million, of which $60 million in cash savings have already flowed through our operating results. Irwin mentioned, Q4 is the timing for our annual impairment testing. In completing our testing this year, we dealt with a number of factors, including the impact of expected inflation on our cost models, increased interest rates, particularly the risk-free interest rates, the strength of the U.S. dollar against our operating currencies, and the general recessionary-like atmosphere, including current market conditions for all publicly traded companies. As a result of these factors and the changes in the market opportunities in front of us, we recorded an impairment of $395 million split between inventory, goodwill, and other intangible assets, all offset by a reduction in deferred income taxes.
The inventory provision partially related to CC Pharma, but was largely related to Aphria One as it prepares for the changes associated with its new relationship with HEXO. As you will recall, certain of HEXO's production processes are moving to our Aphria One facility, and certain of Aphria One's production processes are moving to HEXO's facility. The remaining portion of impairment tied to goodwill and other intangible assets related to our cannabis business segment, portions of which resulted from our ability to focus on our efforts on the best jurisdictional opportunities today. Moving to our business segments in further detail, revenue in our cannabis segment decreased less than 1% to $53.3 million from the prior-year quarter.
If the average foreign exchange rate this year was equal to the rate in the prior year, the revenue in our cannabis segment would have increased 4% to $55.9 million. This decrease included a 4% increase in our Canadian medical cannabis business, a 21.5% decrease in our adult use cannabis business, and a 205% increase in our international cannabis revenue. While our Canadian adult use cannabis revenue decreased, recent market share information from Hifyre for periods after year-end demonstrate our ability to regain lost market share. Regaining this share has been an almost year-long effort working on potency levels and product innovation, combined with increased presence with budtenders.
During the last year, we maintained our belief that the demand for higher quality brands in Canadian adult use cannabis should rise once purchasing decisions are more positively influenced by budtenders within a retail setting. While we are extremely proud of the growth in our international cannabis revenue, the amount in the quarter could have been more. During the quarter, we were scheduled to ship approximately $6 million to an Israeli buyer. However, we chose not to ship such product as we were concerned about our ability to receive payment. Reiterating what Denise said earlier, the Israeli market has become oversupplied with cannabis from the Canadian market. We believe we made the prudent business move by passing on this order.
In terms of profitability and margins, adjusted cannabis gross profit increased 19% to $28.4 million in Q4 from $23.9 million in the prior year quarter, while adjusted gross margin increased 890 basis points to 53.4% from 44.5%. The latter reflected the traction we are making through cost savings as part of our efforts around synergies. Turning to our beverage alcohol business, we generated $22.7 million in net revenue in Q4, which was 43% higher than the prior year quarter. This was primarily due to our acquisition of Breckenridge in December. However, SweetWater contributed an incremental $1.4 million compared to last year due to its extensive new line of innovative products and increased distribution points.
Looking ahead, we believe there is significant upside potential for this segment as we strengthen our position in the U.S. by leveraging our increased distribution, particularly in California, extensive innovation pipelines, and potentially other acquisitions. Adjusted beverage alcohol gross profit increased 28% to $13.6 million in Q4 from $10.6 million in the prior year quarter. However, beverage alcohol gross margins decreased to 60% from 66.5% during this period. Our distribution business, which is overwhelmingly CC Pharma, experienced an 8.3% decline in net revenue during Q4 to $61.2 million from $66.8 million in the prior year quarter. Most of the decline was tied to the strengthening of the U.S. dollar and the inherent weakening of the euro versus the prior year period.
In fact, if the euro-U.S. dollar exchange rate had been the same in the current quarter as it was a year ago, CC Pharma would have reported an additional $6.5 million of revenue. Adjusted distribution gross profit decreased to $3.5 million in Q4 from $6.4 million in the prior year quarter, while distribution gross margin declined to 5.8% from 9.5%. This decline was temporary and due to increased costs as our primary source of products were not able to ship during border closures and during periods of peak demand. We also experienced higher than normal discounts and returns during the quarter. Finally, for our wellness segment, revenue contribution grew to $16.2 million from $5.8 million in Q4 last year, when we only had one month of legacy Tilray results contained within our financials.
We view this business as having stabilized compared to late calendar 2020, as our new leadership team has introduced new products to the portfolio, new distribution points, and reduced the reliance on non-branded big box customers. Adjusted wellness gross profit increased to $5 million in Q4 from $1.6 million in the prior year quarter, while gross margin increased 380 basis points to 30.7% from 26.9%. Last year, we only had one month of Legacy Tilray's wellness business. Consistent with some of my earlier comments, the reduced reliance on non-branded big box customers as well as operating improvements resulted in an increased adjusted gross margins.
Our cash and cash equivalent balance was a healthy $415 million, while our working capital balance increased 9% to $523.2 million and allows us to meet our operational and capital requirements. Notably, we also utilized proceeds from our ATM program to strengthen our balance sheet by paying down approximately $86 million of our convertible debentures in the last quarter, and in doing so, significantly reduced our outstanding debt. Briefly moving to full fiscal 2022 results, net revenue was $628.4 million, an increase of 22% from $513.1 million in 2021. Cannabis revenue grew 17.9%. Distribution revenue was down 6.3%.
While we benefited from contributions from both beverage alcohol, which grew 150% due mostly to acquisitions made over this past year, and wellness, which grew 9x to $59.6 million from $5.8 million as we had 12 full months of contribution versus only one month in the prior fiscal year. On profitability, we increased our adjusted gross profit by 29.2% to $186 million, compared to $143.9 million, and increased adjusted EBITDA by 17.8% to $48 million, compared to $40.8 million in 2021. Included in those results were the synergies we realized from the Aphria-Tilray arrangement.
Of course, notwithstanding those synergies, we will also have substantial cash generation that will be forthcoming as a result of the Tilray and HEXO strategic alliance. As Irwin noted, these additional operation and production efficiencies amount to up to an additional $80 million within the next two years that will be shared by both parties, including our advisory fee of $18 million that HEXO will pay to us during each of the next four years related to cultivation, operations, and production matters. For fiscal 2023, we believe this alliance will generate close to $40 million in additional cash for Tilray. The Canadian market is rightsizing through consolidation and competitive contraction. As this plays out, we are strengthening our position.
This is being accomplished through our broader medical and adult use portfolios of high-quality strains and formats, investments in retail partnerships and physician relationships, optimized product offerings, scaled low-cost production facilities, and our strategic alliance with HEXO. This concludes our prepared remarks. We will now begin the question segment of our call, starting with questions from our covering analysts, which will be followed by a few questions from our retail shareholders through the Say platform. Operator, who has the first question? Hello?
The operator.
Operator?
Thank you. Our first question is from Vivien Azer with Cowen and Company. Please proceed.
Hi, this is actually Victor Ma on for Vivian Azer, and thank you for the questions. My first question: I know post-quarter the trends look better, but recent Hifyre data indicates a 200 basis point volume share loss in both pre-rolls and vapes in the quarter. Can you offer some color on the drivers behind this and the trends in specifically these two categories post-quarter?
For sure. Yeah, I'm gonna let Blair answer that. Blair, as you know, is our president of our Canadian business. Blair, go ahead.
Yeah. There's two trends that are really driving, I would say, our pre-roll numbers and vape numbers, but both trends are different. On the pre-roll side, you're seeing some of our strain rationalization and some of our discontinuation of some brands, which will continue to be a little noisy, but our innovation pipeline will take care of that over time. The second part on vapes, what you're seeing in vapes is a rise in THC, significant rise in THC levels. Again, our innovation pipeline will take care of that, and we're very confident in the trends moving forward.
I don't. As some of the Hifyre data coming out, you know, it's not, as you look at it month by month. It's not always accurate to look at it that way as the different provinces, how they take product in. We definitely don't look at it month by month. I will tell you, right now, last year, this time, we only had a couple new products going in to the OCS. This year, we have over 35 new products and more to come behind it. Our potency levels are up, our price points are up, which we like to see, and we have some incredible programs in place to drive volume. We feel good.
A part of this, what you're seeing too is the Marley brand, which we, you know, took over from, you know, Tilray, is no longer. It's a discontinued brand, which was almost a $30 million business. With that, we've cleaned up SKUs. We did SKU rationalization. In the midst right now, we're coming up with a lot of new products.
Understood. Thank you for the color. If I could just squeeze in one more question on beer. Recent Nielsen data suggests that SweetWater sales underperformed the craft beer category, which fell 2% in July in tracked channels year-over-year. Can you provide any color on the underperformance despite the additional point of distribution states on the U.S. West Coast?
You know, listen, the West Coast is new for us. We have one of the top distributors, Reyes, distributing our products. It's taken a little longer than we expected to go into the West Coast, but we feel really good about SweetWater. SweetWater is taking a little longer than we expected, but we're happy what we're seeing on Green Flash, Nelson and Alpine, and they're our existing brands. Yeah, it's taken a little longer, but I got to tell you, the opportunities on the West Coast are tremendous for SweetWater and our three other brands in that marketplace. We have a great distributor partner in Reyes. What we're seeing also is other distributors that we have today picking up Alpine, Green Flash, in the Southeast.
Our United Distributors just picked some of those products up. The other thing which you're not seeing, you know, in IRI data is what we're doing in regards to on-premise, and we're picking up some nice on-premise business.
Great. Thank you. I'll pop back into the queue.
Our next question is from Andrew Carter with Stifel. Please proceed.
Hey, thanks. Good morning. Well, first up, I wanted to ask, in the guidance here at the midpoint, which is, say, $37 million year-over-year increase. First off, is the HEXO fee included in that number that'll be, I guess, $14-$15 million. But could you also talk through kind of what you're thinking through in terms of FX headwinds, inflation, and also just revenue stability, in particular on the Canadian adult-use business? Thanks.
Morning, Andrew. Yes, the HEXO numbers that I talked about in the call are all included inside of the guidance that we've given. You know, there are a few areas where we're seeing inflationary pressures that are factored into those numbers. We're looking at rising energy costs in Germany. We're looking at rising input material costs at Manitoba Harvest. We also have been able to secure price increases in a few places along the way, and we think that to that point, we won't be adversely impacted.
In terms of kind of the revenue outlook, I mean, is it stability for Canadian adult use? Like, is the timeline for that key to this? Is it by 2Q 2023, 3Q? Just anything you can help us on that line.
On that one, Andrew, you know, I feel it's starting right in Q1. You know, where Blair is seeing you know, growth already and seeing some good things happening at the same time as our new products really go into the marketplace in September. You know, it's not back-end loaded, if that's what you're asking. It basically starts you know, in our first and second quarter. Yeah, it's throughout the year for us. You know, listen, you saw what our margins are. We're not discounting our products like others just to gain share. You saw you know, even still, you know, we continue to grow. We feel good about you know, the Canadian market and where that's going. We feel good about the new products.
Listen, built into there is still synergies from the Aphria-Tilray deal. Not built into those numbers are all the opportunities and synergies with HEXO. We think there's, you know, many, many more. You know, the HEXO ones that are built in, they don't all happen day one. They're throughout the year. There's still opportunities, you know, for additional HEXO deals, HEXO savings.
Thank you. I will pass it on.
Thank you, Andrew.
Our next question is from Andrew Bond with Jefferies. Please proceed.
Hi, good morning. Andrew on the line for Owen Bennett, thank you for taking our questions. First on cannabis margins, very nice lift during the quarter to above 50%. Carl, you mentioned this was driven by efforts around cost savings. Were there any other one-time nuances or items helping lift these margins or any seasonal considerations around cannabis margins we should be making as we forecast fiscal 2023? Or is 4Q a relatively fair representation of underlying cannabis margins, ex any large bulk sales? Thank you.
Andrew, good morning. There is a very small seasonal impact on costs. The growing season from March to May is the best growing season. It's not a huge portion of that number, but it is a small piece of that. The vast majority of the increase, though, has been driven by the cost savings programs. We talked about it in the script a little bit. In addition to the Aphria-Tilray savings that we're targeting, in addition to the Tilray-HEXO piece that we're targeting, we also have an internal plan inside of the cannabis business that we're targeting for further cost reductions.
And then, we put in place throughout the year, you know, some initiatives, you know, how to take additional costs out of our business. That's why we feel good, you know, about cash flow positive, not only, you know, in our Canadian business, in our international business, in our spirits and beer business. You know, the team, after 3.5, 4 years, have done a great job in regards to perfecting our growth and growing to what our plan is. You know, I feel good about where our margins are. Yes, there's some seasonality in there, but, you know, our margins will continue to increase as our volume does and, you know, with our different mix and stuff like that.
Great. Super helpful. Thanks, Irwin. Thanks, Carl. Just really quick, if I may, staying on the same theme, but for non-cannabis CPG. Now that we're entering the warmer summer months here, could you just quickly remind us of the seasonal considerations around beverage alcohol as it relates to on-premise consumption? And related to that, anything to consider, seasonally around Manitoba Harvest? Anything to just help set expectations for quarterly delivery in fiscal 2023 would be helpful. Thank you.
In regards to our Breckenridge, our bourbon, our vodka, our gin businesses, what we're seeing, you know, some great sales right now on our vodka and gin business. There's a lot, and I'm just on our way back from Colorado. Spent the last three days out there for meetings. You know, there's some changes going on in regards to distribution there. We like what we see. You'll see in the back half, you know, our bourbon businesses start to increase. In regards to our seasonality in beer, you know, right now is a strong time for our beer business. With our new distribution going into California and the West Coast, you'll continuously see, you know, increases there. In regards to Manitoba Harvest, I got Jared Simon who runs that. There's no real seasonalities.
I mean, you know, there's a lot of the baking products and that we're coming out with and seeds, different products. You'll see some pickup, you know, as you go into the winter or fall months in regards to baking. From a standpoint there. Just to touch on that, you know, hemp-infused foods, the team has done a tremendous job. What we're coming out with new products, you heard me mention it, you know, in my script, is pretty exciting. We're really excited, you know, about the contribution and the growth coming from our spirits business, our beer business, you know, and our Manitoba Harvest. You know, you heard me talk about wanting to add additional wellness products to our portfolio and additional acquisitions within the spirits and beer business. They're exciting, you know, opportunities for us.
Great. Looking forward to the developments. Thank you. I'll pass it on.
Our next question is from Aaron Grey with Alliance Global Partners. Please proceed.
Hi, good morning, and thank you for the questions.
Morning.
Thank you. Good morning. The first question from me, just wanted to talk a little bit about pricing, specifically around the flower category within Canada. You know, can you speak to, you know, any trends specifically that you're seeing? I know you guys had, you know, taken some price changes, you know, a couple of months ago now. What you kind of see going forward, if you do see some, you know, flooring there, and if it might differentiate between different, you know, categories of premium and value.
Just secondary on that, just, you know, your take on, you know, some asset-light model, you know, that some other LPs might be taking and, you know, whether or not you think that might be more taking advantage of the current dynamics and they might need no cultivation of their own long term, or whether or not that might develop into more of a sustainable model. Thank you.
Yeah. Good morning. Thank you for the question. The flower category is a very interesting category, and if you've looked over the last two to three years, what you've seen is the evolution of these consumer segments around value all the way to what we would call ultra premium. What you'll see in our beta strain program is thoughtfulness around making sure that we have entrants in all of those categories. While value and mainstream continue to be big, set parts of the business, we do see some opportunity in premium and ultra premium, and Broken Coast is our flagship to play there. In terms of the flower category overall, I think you have seen some flooring on it.
I don't think there's much price compression to go, but there are those unique opportunities to premiumize our brands through the different consumer segments, and that is built into our flower innovation program, you know, what you saw late in Q4 on Monkey Butter and Sweet Berry Kush launches. Then going forward, you will continue to see some significant beta strains moving forward.
We think, you know, in regards to, you know, flower, what you're talking about, I mean, the category is changing tremendously, where we're seeing tremendous growth in the pre-roll category and infused pre-rolls and infused flowers. You know, we see the category changing, where flower used to be about 50% of the category, and that's no longer the case. Again, what I feel good about is the quality of our flower, which has improved tremendously, and also is our pre-rolls and our infused pre-rolls and what we're doing, and we're coming out with some slims. We're coming out with some new products, you know, coming in September. I think where we are today, we got the right mix here.
As we talked before, even with, you know, with Hifyre, as we've gone through our SKU rationalization and getting the right types of products into the marketplace, is something that I feel good about where we are on the Canadian market.
All right, great. Thank you for that. Second quick one for me, just on the international front. You talked about some changing dynamics within Israel that are occurring right now. Just given Israel has been a big market for Canadian LPs, as you had some you know slowdown in terms of growth within Germany. Can you talk about you know your outlook for 2023 in terms of you know your P&L and revenue? If there's a slowdown in Israel, do you think incremental growth within the current German medical market you know without expectation for adult use will be enough to offset that, so we still see some meaningful growth on the international side there? Thanks very much.
Hi, Aaron. Thanks for the question. In terms of the international markets, I'm gonna separate out Israel for the moment. We absolutely see growth in our FY 2023 numbers, both in Germany as well as other countries that have come online. As you know, outside of Germany, within Europe, most of the other countries are still fairly small, but we do see growth accelerating in various countries. For instance, looking at the U.K., and even though Luxembourg is pretty small, it's still a good-sized opportunity for us. Plus, in this quarter, we just received our market authorizations for Poland, both on Tilray-branded as well as a private label customer as well, and we are looking to see some big opportunity in Poland.
In France, the medical experiment ends in March 2023, and we are expecting France to legalize medical cannabis soon thereafter. We are well positioned there. Currently in the experiment, we have about 25% share of the customer base, or I should say patient base, and we are very confident that we'll be able to maintain a good market share there. We also see Italy and Spain also making waves and conversation about medical legalization, which we think are also big opportunities for us. You are right, we are not so bullish on Israel. We believe that there is a large oversupply in Israel caused by Canadian LPs shipping into Israel.
I think, what has happened in the marketplace is that as you look at product and oversupplies happening in Canada, Israel was a place where, large amounts of product could be, uploaded, but now that has resulted in an oversupply to that market. What we're seeing is patients, numbers sort of
Stagnating and sales declining. If you look at the marketplace there's a lot of price discounting with, you know, special deals, two for one, three for one. Therefore, we're kind of hitting a little bit of a pause there and looking at what is the right strategy for that market.
Okay, great. Thanks for the call. I'll jump back in the queue.
Our next question is from Tamy Chen with BMO Capital Markets. Please proceed.
Hi. Thanks for the questions. I'm just wondering, you've done a really good job at achieving the cost synergies, and we can really see that in the cannabis gross margin this quarter. I'm just wondering, going forward, in terms of balancing the cost initiatives that you have with the quality of the products. I recall when you did have that stumble in your flower quality last year or something like that. There was the focus on really achieving the cost synergies, but as a result, some of the product quality, especially on flower, deteriorated a bit. I just wanted to better understand what has changed.
What changes have you made in the business so that going forward, as you're identifying more of these cost synergies that you want to achieve, that there isn't going to be a bit of a repeat in terms of quality deteriorating or just not being nimble enough to keep up with trends in the Canadian rec market? Thanks.
Thank you, Tamy. Thank you for your compliments. Number one, you know, like I said before, yes, we've had some quality issues with flower. We acknowledge that. That's over a year ago. I think with automation last year with some heat issues or, you know, in regards to ventilation. You know, that is six to eight months behind us in regards to our quality. The other thing you heard me mention, you know, just on the flower, is where there's a lot of change going on in the marketplace in regards to pre-roll, and that is where some of the bigger growth is coming from. Number one, yes, the team has done a great job in regards to taking out costs.
I will tell you this here, none of that has been taken out to affect quality. Number two, we've invested capital in automation. Number three, we've invested capital in ventilation in regards to, as, you know, with greenhouses and the heat that we, you know, endured last summer. I feel good that costs are not here to hurt our quality. We're in a good place here on regards to potency, some of the genetics that we have in place today. In regards to the mix of the product, you know, with some of the new products that are coming in. You know, the evidence is there by the amount of new products that are being accepted by the different control boards of Tilray Tilray products.
Got it. Thank you. That was it for me.
Thank you.
Our next question is from John Zamparo with CIBC. Please proceed.
Thanks. Good morning. I wanted to start on free cash flow. What was free cash flow in the quarter? And on your free cash guide, you're not adding this disclosure being positive in your operating business unit. Should we interpret that as it may not be positive on a consolidated basis for FY 2023?
Morning, John. Just in the quarter, you know, free cash flow is a pretty generally accepted measure. We burned about $26 .5 million. In that, our forecast for next year is positive free cash flow for the year. And we're saying that's gonna be across the business operating units. I, you know, I'm not sure where you're getting that, one or more of them might be negative. We're forecasting positive for the year.
John, in regards to cash build up this year, a lot of it is just as you come into our seasonality, a big part of it is just building out our inventories, you know, as we go into some of our busy seasonal times. That's what a lot of the cash is used for. Okay. Understood. My second question is on the EBITDA guide. Just would like to better understand this. You're calling for, call it $25 million-$30 million of improvement from FY 2022. You've got the $15 million in incremental synergies from the legacy Aphria deal. You're targeting presumably $40 million in savings from the HEXO deal if you split those cost savings equally.
You're now calling for an additional $30 million in cost savings. You mentioned earlier in the prepared remarks with $5 million saved already. So just can you help us kind of square all that? Or are there multiple incremental costs you're incurring? Is it more that the timing of these synergies is into FY 2024 and 2023? Just anything you can help us understand that would be helpful. Thanks. Well, number one, you know, it's timing. Not everything starts, you know, June 1. I mean, a lot of it, the savings and synergies are spread out throughout the year. It's an annualized basis that we will get over the next 12 months. In regards to HEXO, some of it is interest which is not in EBITDA.
You know, the other thing is, as we continue to grow our business, you know, you'll see our G&A go up as we continue to invest in the infrastructure, you know, of building out the business here. Yes, you know, as we bring on some of the HEXO production and we're just not getting, you know, the HEXO fee for nothing, we have to provide services which will, you know, include adding additional headcount, adding additional people here. There's G&A offsets of some of that coming in. Number one, it's timing. Number two, not all of it is, you know, is interest, which would go into EBITDA here. Three, there's offsets from additional, you know, HEXO in regards to us adding to our infrastructure in G&A.
Okay. That's very helpful. Thanks so much.
Thank you.
Our next question is from Matt Bottomley with Canaccord Genuity. Please proceed.
Yeah, good morning. Thanks for taking these questions. Maybe this one's just for Carl. Just wondering if I could get a little more color on the $395 million of impairment charges. You listed some of the, you know, some of the factors that went into that. Is there anyone that's more, you know, more of a contributing factor? Obviously, with sector valuations continuing to decline, that's something that a lot of LPs and other companies have had to deal with when it comes to how much of the severity of these impairment charges independent of how operations are going. I'm just curious how that factor is impacting the charge versus, you know, independent assumptions you have on growth or risk or things like that in your business segments.
Thanks, Matt. I know in your background, you're a CA as well, so I know you understand this topic fairly well. First off, I just wanna reiterate that impairment is a non-cash charge. Secondly, you know, there are a number of factors that go into the calculation of an impairment when market situations dictate that, right? If you look at what's going on in the market right now, we're effectively in a recession, if it's not formally been called a recession yet. We've got lowering stock price and market cap values for entities. You've got interest rates that are rising. A key component of calculating impairment when required to calculate impairment is what is the discount rate.
Inside of that discount rate, one of the key interest rates is the risk-free rate of return, right? We have all of those pieces impacting our numbers. As we looked at our future cash flows coming out of the cannabis business, we also had to adjust for changing currencies. The Canadian dollar is down against the U.S. dollar. You know, we also had to factor into the equation expectations on inflation. I think when you put all of those together, I would say, you know, it doesn't really change the base beliefs of what is coming out of the cannabis division, but some of the conversion of those pieces into the calculation has caused that difference, which resulted in us taking that non-cash impairment.
You know, it's the if you look at the $395 million number, a portion of it is sitting in inventory, and that was really us getting 301 ready to take on some of the HEXO production that they're going to do, as well as us transferring some of the production on some products to HEXO. We think about $160 million-$170 million of it was goodwill related, and the rest was related to intangibles.
Got it. Very helpful. Thanks. Just one other question for me, and it's more of one of these crystal ball type questions. Specifically in the Canadian market, is there anything that, you know, stakeholders and investors can look at when it comes to potential tailwinds on the regulatory front?
You know, it looks like some of these committee meetings have been punted further down the road with respect to any changes, but when we look at, you know, how high the excise taxes are as a relation to wholesale pricing, you know, what is now kind of a saturated even retail environment, particularly in, you know, the Toronto area where I am at, just anything that, you know, might change for the better that maybe is out of, you know, Tilray or any LP's control, but something that you guys are, you know, hoping for cautiously.
I'm gonna let Blair answer that, but I think it's an excellent question, and we're spending a lot of time, you know, on the Canadian market. Listen, we think in regards to the number of LPs, the number of retail stores will change dramatically. You know, with Tilray, everything is grown and produced within our facility, so you're getting consistent growth, consistent quality. You see what our margins are, you see what our efficiencies are. You know, with that, I feel good about how we're positioned. I'm gonna let Blair speak in a second, but he is, you know, working with the Canadian group that is talking to the government. Sometimes you're talking to yourself when you're talking to the government in regards to excise tax.
We're out there and, you know, it's been delayed in regards to the way the government is gonna look at the cannabis market. There absolutely has to be change to go on in that market. If you come back and think about it, listen, cannabis has contributed over $20 billion in taxes over the last 3.5, four years, $6 billion in building out infrastructure, over 150,000 jobs. In Ontario alone, I think it was $500 million of contribution from cannabis last year. It's contributing a lot of tax dollars, it's contributing employment. Back to your point, about $0.35 of every dollar that we produce goes towards taxes here. The government is doing well. We still can't advertise. We still can't go out and talk about our products.
There's got to be change. You know, we're pushing for it. Blair, anything you wanna add to that?
Yeah. No, what I would just say is, we're very active with C3. I would say from an LP standpoint, the group is very aligned. We had a very successful event in Ottawa back in May. While we don't have the crystal ball, and I know you alluded to that, certainly we do think that, as Irwin said, that we need to see some big change in the regulatory environment.
THC limits are being adjusted in a couple of categories, which is a positive move. We expect to see something from Health Canada today, hopefully around CBD. Certainly there's just a lot of punitive measures going on, whether it be excise or advertising. We continue to push really hard. I would say we're very active with the council, and we will continue to be.
Great. Thanks all. Appreciate all that.
Our next question is from Michael Lavery with Piper Sandler. Please proceed.
Thank you. Good morning.
Good morning.
I just wanted to come back to Israel. I think it was Aaron's question. I know we touched on this a little bit, but you had mentioned the potential sale and then your reluctance to execute it. It sounds like you pointed to market conditions maybe instead of something customer specific. Is it entirely driven by the market? Just to clarify, when you talk about, I think maybe you said it's on a pause, do you have zero sales to Israel in your guidance for this year?
You know, not zero sales, but we're down on sales. Listen, I think, again, Israel is not what? 7 million people. It was a big market. I think it was an area where a lot of sales went in there. There's three things. You know, we got multiple markets. We sell into over 20 countries. We're looking at where there is growth opportunities. I think there's lots of change going on in the way you can sell into Israel and different regulations there. Last but not least, when we sell something, we need to get paid. So that's important, you know, to happen there.
Yeah. Michael, it's Denise. Just to add on to that, because what Irwin said is exactly on point about payment. You know, obviously, we wanna sell and we wanna get paid too, and there has been some issues that have been experienced in the market with payments. I think also the other thing is, there's a lot of changing regulatory environment in Israel where there's you know additional pesticide testing, there are additional requirements that are put on, almost like in an arbitrary fashion. But one thing I would add, just you asked the question of whether we're factoring no sales to Israel. We are actually factoring in sales.
We are looking at it strategically in a different fashion, where we would, rather than simply, you know, having bulk sales go into Israel, we are looking at building out a brand and building out a Tilray presence in Israel. The one thing to note, I think, which is important, is that from a supply chain perspective, our facility is CUMCS certified, totally compliant. We are all ready for the additional pesticide testing that comes online. We are, in fact, ready to sell to Israel if and when we decide that it is the right market conditions and the right terms for us.
We're one of the only ones with the right certification to be able to sell into Israel coming out of our Portugal facility instead of coming out of Canada. You know, we will sell, you know, when it's right, and we will sell knowing we're gonna get paid for it.
Okay, that's helpful. Just would love to follow up with a portfolio question. You mentioned wanting to pursue more acquisitions in beverage alcohol. You've also talked up the benefits of the HEXO arrangement you have now and potentially how it could go further. I guess maybe how do you. You know, is there an order of priority between two of those, and what would it take, what catalyst are you looking for? What conditions would it take for you to wanna push the relationship with HEXO further to, say, like, consolidation or, you know, a bigger ownership stake in the equity?
Number one with HEXO, I think. Listen, this has been a great, you know, deal for Tilray. Again, it's a great deal for HEXO. There's a lot of sharing going on here. You're taking, you know, number one and number two company, and ultimately, will they come together? You know, there's a good chance. I think as you look at the marketplace, you look what they have in grow, what we have in grow, you look at the efficiencies, and that's what the Canadian market needs. You know, I've always said this, there is, you know, over 800 LPs. There's too much grow out there, and you wanna be able to grow in your own facility to be vertically integrated.
What Tilray wants is to be vertically integrated on its own grow, on its, you know, on distribution, on our brands. Today, we have 12 brands. You know, HEXO very much is not a branded company other than Redecan. It's an ingredient company. I think the complementary where we are very much a branded company, where we're vertically integrated on our grow, we have the distribution. You know, Canada is what? 37-38 million people, and you got, you know, two provinces that represent about, what? Three-quarters of the, you know, population and sales. But I think what's important here is consolidation there makes sense, no different than the consolidation with Tilray and Aphria made sense. We took. You know, we'll take over $100 million of cost out.
Just think additionally what we would take out in cost if Tilray and HEXO come together. In regards to, you know, the beer or spirits business, we like that business. We think it's great adjacency in regards to the cannabis industry on numerous fronts. Number one, if you look at the three-tier system, if that's what comes into place, it's going to go through alcohol, you know, distributors. You know, we use Southern Glazer's, which is one of the largest distributors, you know, in the U.S., in Canada, you know, in regards to our salespeople on the street. There's great margins in that business. You know, I'd love to have, you know, the multiple that a Brown-Forman or a Diageo has. That's okay. If you think about it, there's a lot of adjacencies.
The other thing is we are looking at the wellness category in a big way today, as Tilray builds out its brand of consumable business. We think, you know, we have great experience in the wellness area, and we think there's a lot of adjacencies there in regards to our Gen Z or Gen X, you know, and baby boomer consumers.
That's helpful color. Maybe just one follow-up. You mentioned the three-tier system for alcohol. What gives you confidence that cannabis would be handled the same way on any federal legalization in the U.S.?
You know, I don't have any. Listen, I don't have any confidence. I wish there's a crystal ball. You know, the three-tier system has worked well in the alcohol. It's not going away. It's been here forever. I think if you look at it, the three-tier system may be the way it would go. One thing today, I say this here, you know, in our spirits and alcohol business, today, we have a business that has alcohol in it. We'd love to have a business that has, you know, spirits and beer with THC or CBD, and then we have an infrastructure of distributors today that, you know, distribute our beer or our spirits business.
If, you know, legalization happens, that's the case, we can put whatever, you know, we own in the U.S. right in that distribution system, which is a big asset. No one else has that in the cannabis industry today, and that's why we wanna grow that. The same thing, if you come back and look, some of the biggest opportunities out there will be beverages that are infused with THC or CBD and food. I mean, I see what's happening just with our Manitoba Harvest business and our hemp-infused. There's no reason you can't buy potato chips that are not infused with THC or CBD one day, or yogurt that has it spread on top of it. You know, we have
Setting the infrastructure for a lot of these things to happen without knowing what's gonna happen, but we will have it covered in every way.
Okay. Thanks so much.
Our next question is from Scott Fortune with ROTH Capital Partners. Please proceed.
Yeah. Good morning. A lot of questions here, but real quick, just one for me, maybe it's for Denise on the international side. You know, thanks for the update on the Germany legalization progress here and the commercialization by early 2024. But what are you seeing from a competitive environment there in Germany and what are you seeing on the pricing pressures potentially there or what's just kind of a little bit of update on the German competitive and pricing side of things, that'd be great.
Yeah, sure. Hi, Scott. So in terms of the competitive landscape in Germany, both on, I would say, extract and whole flower, we are seeing more and more competition come into the space. Smaller entrants are coming into the space and are posing competition. We continuously watch the competition and stay ahead of the trend. I think one thing, first mover advantage definitely was key here. The German market is not an easy market just to enter. There's a lot of high barriers to entry. One, first and foremost, the registration for products which require stability testing and radiation permits. That process alone can take 12-18 months to complete. Also we're looking at not only on the regulatory side, but we also have very high quality flower.
Actually, just this morning, we received feedback on one of our strains, and it's being touted as one of the top five strains in Germany this morning. We'll continuously look at our market entrance, and we'll continuously compete on high quality flower innovation. I'm also watching pricing as well. Right now we're seeing pricing that on dried flower within the marketplace could go as low as EUR 3.50. We still are seeing our average pricing around the EUR 8.50 price point. We're very pleased with that, and we think that the ability to maintain pricing at that level is having a very high quality product in the marketplace. We are also obviously supplementing all of that with education of health providers and patients as well.
We just launched our WeCare-MedicalCannabis website about a couple of weeks ago, which provides a plethora of information for both healthcare providers and patients. We continue to build brand awareness and continue to maintain high quality flower and innovate across our portfolio.
Thank you. Thanks for that color. I'll leave it at that. Thanks.
Our final question is from Pablo Zuanic with Cantor Fitzgerald. Please proceed.
Good morning, Pablo.
Good morning. This is actually Matthew Baker on for Pablo. Thank you for taking our questions. Gonna focus on the German market. Are you able to consistently ship flower from Portugal to Germany, as we've been hearing different things in the market regarding these types of shipments? Could you just remind us of what you source from Canada versus Portugal regarding the German market? Thank you.
Yeah. Thank you for your question. I am not hearing anything about issues shipping from Portugal. In fact, actually, this is the first time I'm hearing of that. We ship into Germany almost on a weekly basis, so not really sure.
Yeah, I'm not sure where you got that.
Where that comes from. If the question is around adult use legalization, we also have our facility in Germany, which is right now providing medical cannabis to the German government, but there is plenty of room for expansion there in the event of adult use. Well, when there is adult use. We believe that we can provide adult use both from Germany, and we are working on the ability to provide from Portugal as well.
Thank you.
Okay. I got it. Thank you for that. Then just for my follow question, you guys kind of alluded to it in your answer. In the scenario that Germany decides to only import recreational cannabis from within the EU, will you guys need to do anything to adapt for this?
We have capacity within our facility today to allow for the production for adult use. We, as I mentioned, too, have the ability to expand and increase that production quite a bit. We also believe that given the fact that we were the first company to provide medical cannabis to the German government, we have developed a lot of trust and rapport with German officials. We are also currently speaking with German officials as they build out that framework for adult use as we provide our experience in Canada in terms of what works in adult use legalization, what has been problematic in adult use legalization.
There's obviously a lot of questions, and I give a lot of credit to German officials as they are trying to learn and understand what would be best for the German market.
I think the important thing is this here, I mean, I don't think there's enough capacity anywhere to immediately be able to supply the German market. Tilray is the only company that does have two facilities within Europe of scale and size. You know, if it took additional capital and we could, you know, absolutely expand in both, have the know-how, have the ability to do it, and if we were, you know, allowed to ship EU GMP, you know, certified product from Canada, we can do that, too. We are well prepared for the European market upon legalization, and we're probably the only company that would be able to do it.
Thank you for the color.
Thank you.
I'd like to turn the call back over to Berrin Noorata to ask the retail shareholder questions.
Thank you, operator. The first question from the retail shareholder group is, what are you doing to stop the price, the stock price from plummeting?
Thank you, Berrin . Absolutely, you know, a good question. I think and I hope you heard today what we're doing. I hope you heard within our results. If you come back and look, and I just recently came back from a board meeting and presented what Tilray and previous Aphria has done over the last couple of years, in regards to bringing this company together, our plan of how we want to become a $4 billion company, and absolutely that does include, you know, legalization happening. Today, we're a diversified company that is in medical cannabis, adult use cannabis, spirits and beer, and focused on wellness. We have an excellent team. We're focused big on our brands. We're focused on our consumers. Important, you know, it goes back to this question, how do we give back to our shareholders?
In regards to going into next year, being free cash flow positive, being, you know, adjusted EBITDA, you know, increasing our EBITDA and, you know, building out a consumer packaged goods company that's focused on many categories and areas with adjacency to the cannabis industry. Listen, I wish I could go down to Washington tomorrow and knock on President Biden and knock on Congress and Senate and get legalization, you know, to happen, but we can't. I think legalization will happen over the next three to four years. We will be set in regards to our brands, our infrastructure, and have it well surrounded. With our balance sheet, it gives us opportunities to be out there to do different things. I think that's what ultimately, which will increase shareholder value, which increases our stock price.
Thank you, Irwin. The next and last question is, how will you position yourself in order to enter U.S. markets?
Listen, I think again, I go back, we are well-positioned today. You know, we're well-positioned in Canada in regards to brands, our grow, our know-how and knowledge. You know, we have the largest cannabis growing facility in the world today that has the ability to grow 265,000 kilos. We have two facilities in Europe that grow. So with that, we know how to grow. We have 12 great brands in Canada. You know, we have uniqueness and innovation there. You know, we have today between SweetWater, you know, Green Flash, Alpine, Nelson, and our Breckenridge businesses and our Manitoba Harvest business, you know, we have, you know, brands and businesses, with infrastructure and distribution in the U.S. I mean, Manitoba Harvest distributes products to 17,000 stores.
If you think where we sell our beer business and our bourbon business today, and you look at the different distributions. We know how to build brands, we know how to build businesses, we know the adjacencies that are out there. We have the strong balance sheet to do it. With that, depending upon legalization, and if it's one day merging or buy-in with one of the current larger MSOs, we have the ability to do that. We won't forget about MedMen, you know, and have an optionality on MedMen is something we have that upon legalization, we could go ahead and acquire MedMen, which has a strong brand name that can be used in, you know, multiple products throughout the U.S.
We have it circled, and let me tell you, it's difficult running a business with a lot of unknowns out there that are dependent upon regulation. But I think what we're trying to do is build out infrastructure, build out areas upon legalization that we can pull it all together. Thank you. With that ends our call for today. You know, it's been a tough year, 2022, in regards to COVID, in regards to closures in the Canadian market, in regards to having vaccine cards to enter stores, in regards to trying to keep a workforce together, in regards to inflation, in regards to, you know, changing out a lot of our grow, integrating Aphria and Tilray together with the savings, acquiring, you know, our Breckenridge business, acquiring Green Flash, Alpine businesses.
You know, I think we've accomplished a lot in regards to what we're able to do. We built out a very strong management team that can take Tilray to, you know, the next level. Our, you know, deal with HEXO and adjoining with the number two, you know, LP in Canada. With that, I think we're well set and well-positioned for a strong 2023. Listen, we don't like where our stock is, just like everybody else. The market conditions, I think, you know, we're in some tougher times, but with that, you know, Tilray has definitely tightened the belt. We've taken cost out. We're well-positioned on our balance sheet. We're well-positioned on our cash. We're well-positioned in regards to our margins. We're well-positioned on our grow.
We got a good diversified business here, so I'm excited about where we're going, and I'm excited about what we can do. Last but not least, you know, we are focused to return to our shareholders and what we can do with that. With that, enjoy the rest of your summer, and thank you very much for joining our call today. Thank you.
Thank you. This does conclude today's call. You may disconnect your lines at this time, and thank you for your participation.